HA Injection Evidence (Supartz Trial)

→ The August 20 clinic note, added September 12, records four Supartz injections that helped symptoms. Pain with prolonged standing nevertheless persisted. Individual injection dates and the amount/duration of relief are not specified, including the response to the May injection separately. HA is symptom treatment, not evidence of cartilage repair; knee OA evidence does not automatically apply to this postoperative ankle lesion.

Expected Duration of Relief

• 4-6 months is the most consistently reported duration of meaningful pain relief per series across studies [181]
• Hwang et al. (2020): VAS significantly reduced at 12 months in HA after failed microfracture; AOFAS 50.7 → 79.9 at mean 29 months [182]
• For Hepple V cystic lesions, durability is typically at the shorter end because HA does not address subchondral bone pathology

Repeat Dosing: Evidence Is Mostly From Knee OA

The AMELIA Project studied 4 cycles of 5 HA injections over 40 months in 306 people with knee osteoarthritis, not ankle OLT [183]:

• The knee cohort reported a carry-over effect and no new safety signal across repeated cycles
• Large real-world knee data associated more courses with longer time before total knee arthroplasty, but cannot establish cause and effect in an ankle [184]
• These studies do not establish unlimited repeat dosing or durable effectiveness for this ankle
• The July 2026 AAOS guideline strongly recommends against HA alone for symptomatic ankle osteoarthritis; focal postoperative OLT is not identical to diffuse OA, so an individual's measured response still matters [AAOS 2026]

August 2026: The Kennedy Group Reads the Same Evidence and Lands Softer Than AAOS

Published 2026-08-14, the day before this entry — a scoping review of HA across foot and ankle pathology from the NYU Langone foot-and-ankle division, senior author John G. Kennedy, one of the most-published surgeons in talar cartilage [422]. It matters here because it separates the evidence by indication rather than lumping the ankle together:

• The most consistent evidence is for soft-tissue conditions — Achilles tendinopathy, plantar fasciitis, acute lateral ankle injury. Not this lesion.
• For OLT and selected OA, HA is positioned as an adjunct, with outcomes stated plainly as “heterogeneous across studies.”
• The stated limits are the familiar ones: heterogeneous designs, inconsistent protocols, short follow-up — and the paper is Level V, a scoping review, the weakest evidence class on this page.

How this sits against the July 2026 AAOS guideline above: it does not overturn it and does not try to. AAOS graded HA alone for symptomatic ankle OA and recommended strongly against it; this review is looking at a wider set of indications and reaches “adjunct, in selected cases, evidence limited.” Both statements can be true at once, and neither is data about a post-allograft Hepple V lesion. What it changes in practice is small and real: the framing to bring to the August 18 appointment is not “HA versus nothing” but “HA as an adjunct, with a pre-set failure threshold” — which is exactly what the failure criteria below already specify.

August 2026: A Third Reading of the Same Eight Trials — and This One Ranks HA First

Published 2026-08-19, two days after the Kennedy review above — a University of Manchester systematic review that asked the bluntest version of the question on this page: of all the injectable technologies, which one actually works for ankle osteoarthritis? [429]. It restricted itself to randomized controlled trials only, searched five databases back to inception, and found that the entire world literature is eight RCTs.

• HA came out on top: “HA seems to be the most effective in managing AOA symptoms” — either alone as multiple small doses (the Supartz pattern) or combined with corticosteroid or exercise therapy.
• PRP and corticosteroid alone: no evidence of effectiveness. The placebo-controlled PRP trial failed to beat saline — a colder verdict on PRP than the single head-to-head in the combination section below, and from a higher evidence tier.
• Botulinum toxin A also looked effective against the recommended comparator — a genuinely obscure option this page has never had reason to mention before.
• The authors’ own caveat is the honest one: the conclusion “could not be very objective due to how little research there is.” Eight small trials, varying quality.

Where this leaves the three readings. Thirteen months of literature now contain three verdicts on the same tiny RCT base: AAOS (July 2026) — strongly against HA alone; Kennedy [422] — adjunct, outcomes heterogeneous; Manchester [429] — the most effective injectable there is. They are not as contradictory as they sound: AAOS graded HA against doing nothing and found the bar unmet; this review graded HA against the other needles and found it the best of a weakly-evidenced field. Neither is data about a post-allograft Hepple V lesion. What it changes in practice: the cash-pay Supartz series is, per the only RCT-restricted comparison available, the best-supported injectable choice — and the case for adding or switching to PRP just got weaker, not stronger. The failure thresholds below stay exactly where they are.

Added September 18, 2026 — a Level-I look at whether the HA product matters — molecular weight is the only dial with even a weak signal, and everything else the brochures advertise shows nothing

→ A new top-tier analysis pooled 66 randomized trials (9,822 people, all knees) and asked the question this page’s product-comparison section has been running on assumptions about: when you pay for one hyaluronic-acid product over another, what are you actually paying for? The answer: thicker (higher-molecular-weight) formulas trended better for pain, but not convincingly — and the features that differentiate premium products, like cross-linking, concentration, total dose, and injection schedule, showed no independent effect at all. One more exploratory signal: people with milder X-ray damage tended to respond better — the camp this ankle’s early-stage joint sits in. All of it is knee data; none of it is about this ankle. But for a cash-pay decision it points one way: if Supartz keeps working, nothing here says a pricier product would work better — and if it wanes, molecular weight is the only dial worth turning.

Published online 2026-09-17 in the Journal of Cartilage & Joint Preservation, gold open access: a PRISMA systematic review and component network meta-analysis — a design that tries to isolate which ingredients of a treatment carry the effect — of 66 randomized controlled trials, 9,822 participants, all knee osteoarthritis [484]. Findings: ultra-high- and high-molecular-weight formulations showed the most favorable directional estimates for intermediate-term pain relief, but confidence intervals were wide and superiority was not established; an exploratory component model associated higher molecular weight with greater pain reduction (β = −0.78, P = .030), which the authors themselves demote to hypothesis-generating because the formulation characteristics travel together (collinearity) and the model’s additivity assumption did not hold; and no statistically significant independent association was found for cross-linking, concentration, cumulative dose, or injection schedule. Exploratory analyses suggested less advanced radiographic disease may respond better, without a statistically reliable interaction. Certainty: moderate-to-low for pain, very low for the component effects.

What this changes on this page. The product-comparison section below has rested on the Witteveen Cochrane finding of “no clear product superiority” in the ankle [185]; this is the knee literature’s far larger version of the same question, asked with better tools, and it lands close by: a directional-only case for higher molecular weight, and an explicit null for the cross-linking and dosing features that carry most of the price differences. For the standing “if Supartz wanes” contingency, that sharpens the sequence rather than changing it — a switch would reach for higher molecular weight specifically, not for cross-linking as such — and it removes any evidence-based pressure to preemptively upgrade away from a mid-MW product that is measurably helping. The early-disease signal points the same direction as Han 2014’s Takakura I–II predictor already on this page [186]. Honest limits: every one of the 66 trials is a knee trial — the joint discount at the top of this page applies in full; the molecular-weight component estimate is exploratory by the authors’ own grading, not a demonstrated causal effect; and a formulation analysis says nothing about whether HA addresses this lesion’s subchondral bone problem, which it does not.

Product Comparison — If Supartz Wanes

Supartz is mid-MW linear HA. If response diminishes, options include:

• Cross-linked HMW products (Synvisc-One, Monovisc, Durolane): potentially longer intra-articular residence, but higher rate of post-injection flare reactions (~2.5%)
• Euflexxa: bio-fermented (non-avian), higher MW, useful if avian allergy concern
• No head-to-head ankle data shows clear product superiority — the Witteveen Cochrane review found similar modest benefits across products [185]

Predictors of Response (Han 2014)

Yonsei Medical Journal study of 40 patients found [186]:

• Positive predictors: early-stage disease (Takakura I-II), symptom duration <12 months
• NOT predictive: age, gender, fracture history, subchondral cysts
• 12-month outcomes: 40% completely satisfied, 35% dissatisfied

Failure Criteria — When to Escalate

• Set MCID thresholds before each series (AOFAS ≥10 points, VAS ≥2 points)
• If <3 months of meaningful relief per series, or ≥2 failed series → consider next-line
• Hwang 2020: 33% of HA-after-failed-microfracture patients went on to further surgery within mean 29 months
• For Hepple V: failure criteria should be tighter because HA can't fix the underlying bone problem

Off-Label Use and Insurance Reality

• FDA-approved for KNEE OA only. ALL ankle use is off-label
• Medicare LCD L39260 and most commercial insurers: HA "investigative and not covered" for ankle
• Most common outcome: denial. Patients pay cash ($300-$1200 per injection)
• Switching from Kaiser to PPO may help with appeal-based coverage but doesn't change FDA off-label status
• Boffa/Filardo 2021 systematic review (24 studies): significant benefit favoring HA vs saline at 6 months for ankle OA, GRADE evidence quality "very low" [187]

Combination Therapies Worth Considering

• HA + PRP: Mei-Dan 2012 head-to-head — PRP slightly superior to HA alone for talar OLT (VAS 4.1→0.9 PRP vs 5.6→3.1 HA) [188]
• HA + BMAC + scaffold: Buda 10-year data shows durable results for cystic OLT (this is surgical, not injection) [189]
• HA + corticosteroid: Avoid in young patient — steroid is chondrotoxic with repeated use

Long-Term Safety

• Per-injection AE rate: 1-4%; serious AEs <0.01%
• Repeated courses are at least as safe, probably safer than first course
• No cumulative toxicity, no chondrotoxicity (unlike corticosteroids)
• Main risk is opportunity cost — delaying definitive treatment of a Hepple V cystic lesion